Relationship between glycosylated hemoglobin and iron deficiency anemia: A common but overlooked problem

Relationship between glycosylated hemoglobin and iron deficiency anemia: A common but overlooked problem

•Our study has shown that IDA is related to increased HbA1c concentrations and HbA1c decreases following treatment with iron.•Making any decisions regarding diagnosis or treatment according to HbA1c, IDA should be considered.•Early diagnosis and treatment of IDA in diabetic patients may improve glyc...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Primary care diabetes 2022-04, Vol.16 (2), p.312-317
Hauptverfasser: Aydın, Bünyamin, Özçelik, Serhat, Kilit, Türkan Paşalı, Eraslan, Sertaç, Çelik, Mehmet, Onbaşı, Kevser
Format: Artikel
Sprache:eng
Schlagworte:
Anemia
Glycosylated hemoglobin
Iron deficiency
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 317
container_issue 2
container_start_page 312
container_title Primary care diabetes
container_volume 16
creator Aydın, Bünyamin
Özçelik, Serhat
Kilit, Türkan Paşalı
Eraslan, Sertaç
Çelik, Mehmet
Onbaşı, Kevser
description •Our study has shown that IDA is related to increased HbA1c concentrations and HbA1c decreases following treatment with iron.•Making any decisions regarding diagnosis or treatment according to HbA1c, IDA should be considered.•Early diagnosis and treatment of IDA in diabetic patients may improve glycemic control. Both diabetes mellitus (DM) and iron deficiency anemia (IDA) are prevalent in every area of the world, and so, the possibility of these two diseases co-existing is also very high. It is our belief that clinical results of any correlation between iron status of the body and glycosylated haemoglobin (HbA1c) would be beneficial to many patients, therefore in this study, the effect of IDA on HbA1c was investigated. A total of 146 patients with DM and IDA were evaluated prospectively. While the patients were administered 270 mg/day of ferrous sulphate (80 mg elemental iron) orally for three months for the treatment of IDA, no interventions were made for the treatment of DM. Patient levels of hemoglobin (Hb), hematocrit, red blood cells (RBC), mean corpuscular volume (MCV), platelet, white blood cells (WBC), serum iron, serum iron binding capacity (SIBC), ferritin, fasting plasma glucose (FPG), HbA1c, body mass index (BMI), C-reactive protein (CRP) values were measured at baseline and at the third month of treatment with iron, and were compared. The median age of our patients was 45 (40–50) and median duration of diabetes was 3 years (1,75–5). While the baseline median Hb was 10.4 (mg/dL) (9.5–11.1), MCV was 74 (fL) (70.8–77), ferritin was 4 (ug/L) (3–6) at three months, Hb was measured at 12.6 (mg/dL) (12.1–13.2), MCV was measured at 82 (fL) (80–86), ferritin was measured at 15 (ug/L) (9–21.2) and was significantly higher compared to baseline values (p 
doi_str_mv 10.1016/j.pcd.2022.01.002
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2618516567</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S175199182200002X</els_id><sourcerecordid>2618516567</sourcerecordid><originalsourceid>FETCH-LOGICAL-c353t-68e94e5a41736b3948b9cc962e47ca1f2d159da6b6e2b0337632ba4d146e62273</originalsourceid><addsrcrecordid>eNp9kMlu2zAQhokiQe0meYBcCh5zkcohJUpqToaRLoCBAEVyJriMYzqS6JJyAr996TrNsScS_JcZfoRcAyuBgfyyLXfWlZxxXjIoGeMfyBzapi0YB3aW700NRddBOyOfUtoyJkG0zUcyEzVjrO2qOdn8wl5PPoxp43fU4PSKONKn_mBDOmQFHd3gEJ76YPxI9eioj2GkDtfeehztIb_h4PVXuqA2DEPWzH6i4QVjH8Jzju9iMD0Ol-R8rfuEV2_nBXn8dvew_FGs7r__XC5WhRW1mArZYldhrStohDSiq1rTWdtJjlVjNay5g7pzWhqJ3DAhGim40ZWDSqLkvBEX5ObUm-f-3mOa1OCTxb7Pe4Z9UlxCW4Os5dEKJ6uNIaWIa7WLftDxoICpI2C1VRmwOgJWDFQGnDOf3-r3ZkD3nvhHNBtuTwbMn3zxGFX6Cwqdj2gn5YL_T_0f8dWMQw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2618516567</pqid></control><display><type>article</type><title>Relationship between glycosylated hemoglobin and iron deficiency anemia: A common but overlooked problem</title><source>Elsevier ScienceDirect Journals Complete</source><creator>Aydın, Bünyamin ; Özçelik, Serhat ; Kilit, Türkan Paşalı ; Eraslan, Sertaç ; Çelik, Mehmet ; Onbaşı, Kevser</creator><creatorcontrib>Aydın, Bünyamin ; Özçelik, Serhat ; Kilit, Türkan Paşalı ; Eraslan, Sertaç ; Çelik, Mehmet ; Onbaşı, Kevser</creatorcontrib><description>•Our study has shown that IDA is related to increased HbA1c concentrations and HbA1c decreases following treatment with iron.•Making any decisions regarding diagnosis or treatment according to HbA1c, IDA should be considered.•Early diagnosis and treatment of IDA in diabetic patients may improve glycemic control. Both diabetes mellitus (DM) and iron deficiency anemia (IDA) are prevalent in every area of the world, and so, the possibility of these two diseases co-existing is also very high. It is our belief that clinical results of any correlation between iron status of the body and glycosylated haemoglobin (HbA1c) would be beneficial to many patients, therefore in this study, the effect of IDA on HbA1c was investigated. A total of 146 patients with DM and IDA were evaluated prospectively. While the patients were administered 270 mg/day of ferrous sulphate (80 mg elemental iron) orally for three months for the treatment of IDA, no interventions were made for the treatment of DM. Patient levels of hemoglobin (Hb), hematocrit, red blood cells (RBC), mean corpuscular volume (MCV), platelet, white blood cells (WBC), serum iron, serum iron binding capacity (SIBC), ferritin, fasting plasma glucose (FPG), HbA1c, body mass index (BMI), C-reactive protein (CRP) values were measured at baseline and at the third month of treatment with iron, and were compared. The median age of our patients was 45 (40–50) and median duration of diabetes was 3 years (1,75–5). While the baseline median Hb was 10.4 (mg/dL) (9.5–11.1), MCV was 74 (fL) (70.8–77), ferritin was 4 (ug/L) (3–6) at three months, Hb was measured at 12.6 (mg/dL) (12.1–13.2), MCV was measured at 82 (fL) (80–86), ferritin was measured at 15 (ug/L) (9–21.2) and was significantly higher compared to baseline values (p &lt; 0.001). The baseline median HBA1c of patients was 7.09 ± 0.51 (%) and three month HBA1c was 6.69 ± 0.53 (%), which was significantly lower than when comparing baseline values with values at third month (p &lt; 0.001). Baseline and three month values for FPG were 118 (mg/dL) (108–132) and 116 (mg/dL) (106–125) respectively, and there was no significant difference (p:0.07). A 2.2 mg/dL (1.5–3.5) increase in median Hb level accompanied a 0.4 % (0.2–0.6) decrease in median HbA1c levels (Spearman rho = −0.362; p &lt; 0.001). Our study has shown conclusivly that IDA is related to increased HbA1c concentrations and HbA1c decreases significantly following treatment with iron. IDA should be considered before making any decisions regarding diagnosis or treatment according to HbA1c.</description><identifier>ISSN: 1751-9918</identifier><identifier>EISSN: 1878-0210</identifier><identifier>DOI: 10.1016/j.pcd.2022.01.002</identifier><identifier>PMID: 35000894</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Anemia ; Glycosylated hemoglobin ; Iron deficiency</subject><ispartof>Primary care diabetes, 2022-04, Vol.16 (2), p.312-317</ispartof><rights>2022 Primary Care Diabetes Europe</rights><rights>Copyright © 2022 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c353t-68e94e5a41736b3948b9cc962e47ca1f2d159da6b6e2b0337632ba4d146e62273</citedby><cites>FETCH-LOGICAL-c353t-68e94e5a41736b3948b9cc962e47ca1f2d159da6b6e2b0337632ba4d146e62273</cites><orcidid>0000-0003-2230-9263 ; 0000-0003-1126-7336</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.pcd.2022.01.002$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35000894$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Aydın, Bünyamin</creatorcontrib><creatorcontrib>Özçelik, Serhat</creatorcontrib><creatorcontrib>Kilit, Türkan Paşalı</creatorcontrib><creatorcontrib>Eraslan, Sertaç</creatorcontrib><creatorcontrib>Çelik, Mehmet</creatorcontrib><creatorcontrib>Onbaşı, Kevser</creatorcontrib><title>Relationship between glycosylated hemoglobin and iron deficiency anemia: A common but overlooked problem</title><title>Primary care diabetes</title><addtitle>Prim Care Diabetes</addtitle><description>•Our study has shown that IDA is related to increased HbA1c concentrations and HbA1c decreases following treatment with iron.•Making any decisions regarding diagnosis or treatment according to HbA1c, IDA should be considered.•Early diagnosis and treatment of IDA in diabetic patients may improve glycemic control. Both diabetes mellitus (DM) and iron deficiency anemia (IDA) are prevalent in every area of the world, and so, the possibility of these two diseases co-existing is also very high. It is our belief that clinical results of any correlation between iron status of the body and glycosylated haemoglobin (HbA1c) would be beneficial to many patients, therefore in this study, the effect of IDA on HbA1c was investigated. A total of 146 patients with DM and IDA were evaluated prospectively. While the patients were administered 270 mg/day of ferrous sulphate (80 mg elemental iron) orally for three months for the treatment of IDA, no interventions were made for the treatment of DM. Patient levels of hemoglobin (Hb), hematocrit, red blood cells (RBC), mean corpuscular volume (MCV), platelet, white blood cells (WBC), serum iron, serum iron binding capacity (SIBC), ferritin, fasting plasma glucose (FPG), HbA1c, body mass index (BMI), C-reactive protein (CRP) values were measured at baseline and at the third month of treatment with iron, and were compared. The median age of our patients was 45 (40–50) and median duration of diabetes was 3 years (1,75–5). While the baseline median Hb was 10.4 (mg/dL) (9.5–11.1), MCV was 74 (fL) (70.8–77), ferritin was 4 (ug/L) (3–6) at three months, Hb was measured at 12.6 (mg/dL) (12.1–13.2), MCV was measured at 82 (fL) (80–86), ferritin was measured at 15 (ug/L) (9–21.2) and was significantly higher compared to baseline values (p &lt; 0.001). The baseline median HBA1c of patients was 7.09 ± 0.51 (%) and three month HBA1c was 6.69 ± 0.53 (%), which was significantly lower than when comparing baseline values with values at third month (p &lt; 0.001). Baseline and three month values for FPG were 118 (mg/dL) (108–132) and 116 (mg/dL) (106–125) respectively, and there was no significant difference (p:0.07). A 2.2 mg/dL (1.5–3.5) increase in median Hb level accompanied a 0.4 % (0.2–0.6) decrease in median HbA1c levels (Spearman rho = −0.362; p &lt; 0.001). Our study has shown conclusivly that IDA is related to increased HbA1c concentrations and HbA1c decreases significantly following treatment with iron. IDA should be considered before making any decisions regarding diagnosis or treatment according to HbA1c.</description><subject>Anemia</subject><subject>Glycosylated hemoglobin</subject><subject>Iron deficiency</subject><issn>1751-9918</issn><issn>1878-0210</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kMlu2zAQhokiQe0meYBcCh5zkcohJUpqToaRLoCBAEVyJriMYzqS6JJyAr996TrNsScS_JcZfoRcAyuBgfyyLXfWlZxxXjIoGeMfyBzapi0YB3aW700NRddBOyOfUtoyJkG0zUcyEzVjrO2qOdn8wl5PPoxp43fU4PSKONKn_mBDOmQFHd3gEJ76YPxI9eioj2GkDtfeehztIb_h4PVXuqA2DEPWzH6i4QVjH8Jzju9iMD0Ol-R8rfuEV2_nBXn8dvew_FGs7r__XC5WhRW1mArZYldhrStohDSiq1rTWdtJjlVjNay5g7pzWhqJ3DAhGim40ZWDSqLkvBEX5ObUm-f-3mOa1OCTxb7Pe4Z9UlxCW4Os5dEKJ6uNIaWIa7WLftDxoICpI2C1VRmwOgJWDFQGnDOf3-r3ZkD3nvhHNBtuTwbMn3zxGFX6Cwqdj2gn5YL_T_0f8dWMQw</recordid><startdate>202204</startdate><enddate>202204</enddate><creator>Aydın, Bünyamin</creator><creator>Özçelik, Serhat</creator><creator>Kilit, Türkan Paşalı</creator><creator>Eraslan, Sertaç</creator><creator>Çelik, Mehmet</creator><creator>Onbaşı, Kevser</creator><general>Elsevier Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-2230-9263</orcidid><orcidid>https://orcid.org/0000-0003-1126-7336</orcidid></search><sort><creationdate>202204</creationdate><title>Relationship between glycosylated hemoglobin and iron deficiency anemia: A common but overlooked problem</title><author>Aydın, Bünyamin ; Özçelik, Serhat ; Kilit, Türkan Paşalı ; Eraslan, Sertaç ; Çelik, Mehmet ; Onbaşı, Kevser</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c353t-68e94e5a41736b3948b9cc962e47ca1f2d159da6b6e2b0337632ba4d146e62273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Anemia</topic><topic>Glycosylated hemoglobin</topic><topic>Iron deficiency</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aydın, Bünyamin</creatorcontrib><creatorcontrib>Özçelik, Serhat</creatorcontrib><creatorcontrib>Kilit, Türkan Paşalı</creatorcontrib><creatorcontrib>Eraslan, Sertaç</creatorcontrib><creatorcontrib>Çelik, Mehmet</creatorcontrib><creatorcontrib>Onbaşı, Kevser</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Primary care diabetes</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aydın, Bünyamin</au><au>Özçelik, Serhat</au><au>Kilit, Türkan Paşalı</au><au>Eraslan, Sertaç</au><au>Çelik, Mehmet</au><au>Onbaşı, Kevser</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Relationship between glycosylated hemoglobin and iron deficiency anemia: A common but overlooked problem</atitle><jtitle>Primary care diabetes</jtitle><addtitle>Prim Care Diabetes</addtitle><date>2022-04</date><risdate>2022</risdate><volume>16</volume><issue>2</issue><spage>312</spage><epage>317</epage><pages>312-317</pages><issn>1751-9918</issn><eissn>1878-0210</eissn><abstract>•Our study has shown that IDA is related to increased HbA1c concentrations and HbA1c decreases following treatment with iron.•Making any decisions regarding diagnosis or treatment according to HbA1c, IDA should be considered.•Early diagnosis and treatment of IDA in diabetic patients may improve glycemic control. Both diabetes mellitus (DM) and iron deficiency anemia (IDA) are prevalent in every area of the world, and so, the possibility of these two diseases co-existing is also very high. It is our belief that clinical results of any correlation between iron status of the body and glycosylated haemoglobin (HbA1c) would be beneficial to many patients, therefore in this study, the effect of IDA on HbA1c was investigated. A total of 146 patients with DM and IDA were evaluated prospectively. While the patients were administered 270 mg/day of ferrous sulphate (80 mg elemental iron) orally for three months for the treatment of IDA, no interventions were made for the treatment of DM. Patient levels of hemoglobin (Hb), hematocrit, red blood cells (RBC), mean corpuscular volume (MCV), platelet, white blood cells (WBC), serum iron, serum iron binding capacity (SIBC), ferritin, fasting plasma glucose (FPG), HbA1c, body mass index (BMI), C-reactive protein (CRP) values were measured at baseline and at the third month of treatment with iron, and were compared. The median age of our patients was 45 (40–50) and median duration of diabetes was 3 years (1,75–5). While the baseline median Hb was 10.4 (mg/dL) (9.5–11.1), MCV was 74 (fL) (70.8–77), ferritin was 4 (ug/L) (3–6) at three months, Hb was measured at 12.6 (mg/dL) (12.1–13.2), MCV was measured at 82 (fL) (80–86), ferritin was measured at 15 (ug/L) (9–21.2) and was significantly higher compared to baseline values (p &lt; 0.001). The baseline median HBA1c of patients was 7.09 ± 0.51 (%) and three month HBA1c was 6.69 ± 0.53 (%), which was significantly lower than when comparing baseline values with values at third month (p &lt; 0.001). Baseline and three month values for FPG were 118 (mg/dL) (108–132) and 116 (mg/dL) (106–125) respectively, and there was no significant difference (p:0.07). A 2.2 mg/dL (1.5–3.5) increase in median Hb level accompanied a 0.4 % (0.2–0.6) decrease in median HbA1c levels (Spearman rho = −0.362; p &lt; 0.001). Our study has shown conclusivly that IDA is related to increased HbA1c concentrations and HbA1c decreases significantly following treatment with iron. IDA should be considered before making any decisions regarding diagnosis or treatment according to HbA1c.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>35000894</pmid><doi>10.1016/j.pcd.2022.01.002</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-2230-9263</orcidid><orcidid>https://orcid.org/0000-0003-1126-7336</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1751-9918
ispartof Primary care diabetes, 2022-04, Vol.16 (2), p.312-317
issn 1751-9918
1878-0210
language eng
recordid cdi_proquest_miscellaneous_2618516567
source Elsevier ScienceDirect Journals Complete
subjects Anemia
Glycosylated hemoglobin
Iron deficiency
title Relationship between glycosylated hemoglobin and iron deficiency anemia: A common but overlooked problem
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T08%3A46%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Relationship%20between%20glycosylated%20hemoglobin%20and%20iron%20deficiency%20anemia:%20A%20common%20but%20overlooked%20problem&rft.jtitle=Primary%20care%20diabetes&rft.au=Ayd%C4%B1n,%20B%C3%BCnyamin&rft.date=2022-04&rft.volume=16&rft.issue=2&rft.spage=312&rft.epage=317&rft.pages=312-317&rft.issn=1751-9918&rft.eissn=1878-0210&rft_id=info:doi/10.1016/j.pcd.2022.01.002&rft_dat=%3Cproquest_cross%3E2618516567%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2618516567&rft_id=info:pmid/35000894&rft_els_id=S175199182200002X&rfr_iscdi=true